SRC and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib, along with other TKIs, is an ABL/SRC tyrosine kinase inhibitor used in the first-line treatment of chronic myeloid leukaemia (CML) and potently induces apoptosis of CML cells [132,133,134].